TrovaGene Stock Company Profile

Description

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples, as well as intends to provide clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung cancer, as well as targeting clinically validated gene rearrangements, such as ALK, RET, and ROS. In addition, it offers laboratory developed tests for oncogene mutations to end users through a sales and marketing organization. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.